News | January 04, 2013

Biotronik Home Monitoring Reduces Inappropriate ICD Shocks by 52 Percent

ECOST trial results published in European Heart Journal

Biotronik Home Monitoring ECOST Clinical Trial ICDs

January 4, 2013 — Biotronik announced that the European Heart Journal has published the clinical results of the ECOST trial (Effectiveness and Cost of ICD Follow-Up Schedule with Telecardiology). The randomized controlled study evaluated the safety and efficacy of Biotronik Home Monitoring compared with standard in-office follow-up visits for patients with implantable cardioverter-defibrillators (ICDs).

Results from ECOST provide pioneering scientific evidence that continuous remote monitoring with Biotronik Home Monitoring reduces inappropriate shocks, may improve battery longevity in long-term follow-up of patients implanted with an ICD and is as safe as, sometimes even safer than standard in-office follow-ups. This outcome is consistent with previous findings from studies such as the landmark TRUST trial.[1,2]

ECOST is a prospective multicenter clinical trial designed to examine the safety and efficacy of remote monitoring of ICD patients with Biotronik Home Monitoring over 27 months. The study analyzed 433 patients from 43 sites throughout France who were randomly assigned to home monitoring follow-up or standard in-office care. The 221 home monitoring patients (the active group) were seen in the ambulatory department once per year, unless home monitoring reported a technical or clinical event requiring an in-office visit. The 212 control group patients underwent in-office visits every six months.

During a two-year period, the overall number of delivered shocks in the home monitoring group were 71 percent lower than in the control group — a significant decrease. Furthermore, the proportion of patients who received inappropriate shocks was 52 percent lower in the home monitoring group than in the control group. While some remote monitoring technologies can drain the device battery in the long term, daily BIOTRONIK Home Monitoring retains ICD battery life: ECOST showed a 76 percent reduction in the number of capacitor charges for the Biotronik Home Monitoring group (499 vs. 2081), resulting in extended device longevity.

“The ECOST trial results prove Biotronik Home Monitoring reduces inappropriate shocks in patients and also positively extends the ICD’s battery longevity,” said Professor Salem Kacet, principal investigator of the ECOST study. “This advanced technology is very important for the observation of arrhythmias and early adaptation of ICD therapy. Patients benefit from the reduced risk of inappropriate shocks — which can be a very unpleasant experience — and need ICD replacement less frequently.”

For more information: www.biotronik.com

References

1 Varma et al., Circulation, 2010, 122, 325–332.

2 Varma et al., Circ Arrhythm Electrophysiol, 2010, 3:428–436.

Related Content

Smartphone Apps Help Patients and Providers Manage Atrial Fibrillation
News | Patient Engagement| October 19, 2017
October 19, 2017 — Novel smartphone and tablet applications for atrial fibrillation patients and healthcare professio
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
Overlay Init